18th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160120797 | ANTI-ACNE COMPOSITION AND METHODS OF USE THEREOF - The present invention provides for a topical dermatological composition that includes diclofenac and clindamycin, in a pharmaceutically acceptable medium, wherein at least one of the diclofenac and clindamycin is at least partially microencapsulated. | 2016-05-05 |
20160120798 | TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE - Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical formulation comprising a therapeutically effective amount of trehalose. | 2016-05-05 |
20160120799 | Methods of using Microneedle Vaccine Formulations to Elicit in Animals Protective Immunity against Rabies Virus - The present invention relates to microneedle vaccine formulations, as well as methods of use thereof to provide animals, including canines, protective immunity against infection and disease caused by rabies viruses. Once placed onto the skin of the animals, the microneedle formulations dissolve quickly into the surrounding skin, where the antigens then elicit in the animals high and protective levels of rabies virus neutralizing antibodies. | 2016-05-05 |
20160120800 | INTRAVAGINAL DRUG DELIVERY DEVICE COMPRISING A POLYURETHANE COPOLYMER - Intravaginal drug delivery device comprising at least one pharmaceutically active substance, and a polyurethane copolymer, wherein the copolymer has the structure according to formula (I): | 2016-05-05 |
20160120801 | USE OF A THIAZOLO PYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (compound A) in the range of 2.5 mg to 60 mg. Present invention also relates to a method of treating inflammatory bowel disease in a mammal by administrating said low dose pharmaceutical composition. Further, present invention relates to a use of the compound A for the preparation of low dose pharmaceutical composition for the treatment of inflammatory bowel disease in a mammal. | 2016-05-05 |
20160120802 | ORALLY-DISINTEGRATING OSELTAMIVIR TABLET AND METHOD FOR PREPARING THE SAME - An orally-disintegrating oseltamivir tablet, including: between 10 and 50 wt. % of a taste-masking pellet, between 30 and 80 wt. % of a first filler, between 1 and 6 wt. % of a first adhesive, between 2 and 10 wt. % of a disintegrant, between 0 and 5 wt. % of a flavoring agent, between 0.5 and 2.5 wt. % of a lubricant. The taste-masking pellet includes: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt of oseltamivir and accounts for between 10 and 40 wt. % of a total weight of the taste-masking pellet. The coating layer include a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the taste-masking pellet. The diameter of the taste-masking pellet is between 0.10 and 0.50 mm. | 2016-05-05 |
20160120803 | NON-AEROSOL FOAMS FOR TOPICAL ADMINISTRATION - Disclosed are liquid compositions suitable for topical administration and for use with a non-aerosol pump, wherein actuation of the pump produces a foam, the composition comprising: (a) about 1% to about 8% (w/w) foam booster; (b) about 0.4% to about 5% (w/w) foaming agent; and (c) about 20% to about 98% (w/w) solubilizer; and, optionally, (d) about 0.5% to about 5% (w/w) emollient; wherein the composition is substantially free of propellant. Also disclosed are the foams produced by such pump actuation. | 2016-05-05 |
20160120804 | LIPOSOMES FOR MODULATING WISKOTT-ALDRICH SYNDROME PROTEIN - Embodiments of the invention relate to liposomes comprising: a lipid bilayer having an internal cavity; a therapeutic agent within the internal cavity configured to modify expression or degradation of WASp in a cell; and a targeting moiety external to the lipid bilayer configured to target an extracellular domain of a cell. Embodiments of the invention relate to methods of treatment of disease comprising administering the liposomes. Novel pharmaceutical compositions are also disclosed. | 2016-05-05 |
20160120805 | EXOSOMES FOR OROFACIAL DIAGNOSTICS AND THERAPEUTICS - Provided are methods of treating a subject with a composition comprising an exosome or a polypeptide, RNA, or miRNA contained therein or identified or isolated therefrom. Also provided are methods of promoting dentinogenesis, amelogenesis, or osteogenesis. Also provided are compositions comprising an exosome or a polypeptide, RNA, or miRNA contained therein or identified or isolated therefrom. | 2016-05-05 |
20160120806 | NANOCRYSTALS FORMED IN A MICROENVIRONMENT - A formulation is disclosed which is comprised of a first solvent having a first active ingredient dissolved therein a plurality of microenvironments dispersed in the first solvent, the microenvironment being comprised of a shell having a dimension in a range of 50 nanometers to 100, the shell comprising an internal volume comprising a second solvent having a second active ingredient dissolved therein and nanocrystals of the second active ingredient. | 2016-05-05 |
20160120807 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS - A lipid vesicle comprising a functionalized lipid comprising a tether moiety having binding affinity for a ligand portion of an active agent and the active agent are provided. Methods of decorating endothelial cells, tissues, and organs with active agents utilizing the disclosed lipid vesicles are also provided. | 2016-05-05 |
20160120808 | 3D Printing of Digestible Shells For Medicaments - A method for producing edible medications comprises providing a three-dimensional (3D) model of the edible medication including an internal cavity sized and shaped for receipt of a medicament therein, printing an edible media to form a portion of the 3D shell corresponding to the model for introduction of the medicament, and then printing the edible media to form the remainder of the 3D shell to completely enclose the medicament within the edible media. | 2016-05-05 |
20160120809 | ORALLY DISINTEGRATING TABLET FORMULATION FOR ENHANCED BIOAVAILABILITY - In some aspects of the present invention is a formulation comprising a solid dispersion or intimate mixture of a poorly water soluble drug and an ionic polymer surprisingly exhibiting fast disintegration of tablet. | 2016-05-05 |
20160120810 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 2016-05-05 |
20160120811 | METHODS OF ADMINISTERING ANTIHISTAMINES - Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed. | 2016-05-05 |
20160120812 | Methods of Preparing Tamper Resistant Solid Oral Dosage Forms - Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent. | 2016-05-05 |
20160120813 | FUNCTIONAL POLYMER FILM-COATED PARTICLE HAVING HIGH DRUG CONTENT, TABLET CONTAINING SAME, AND METHODS FOR PRODUCTION THEREOF - Provided are functional drug-containing particles which can be compressed into tablets and in particular, to orally disintegrating tablets by employing any of a dry molding method, a wet molding method, or a humidifying drying method. The functional drug-containing particles comprise substantially spherical drug-containing particles essentially including drug and a binder, the functional drug-containing particles including a functional polymer film selected from the group consisting of an enteric film, a release control film, and a bitter taste masking film, an average particle diameter of said functional drug-containing particles being 400 μm or less, a particle diameter ratio D | 2016-05-05 |
20160120814 | Method for Preparing Protein Cage, and In Situ Method for Preparing Hydrophobic Additive-supported Core-shell Structured Polymer-protein Particles - The present invention relates to a method for preparing a protein cage which comprises: a 1 | 2016-05-05 |
20160120815 | MICROSPHERES OF PANCREATIC ENZYMES WITH HIGH STABILITY AND PRODUCTION METHOD THEREOF - The present invention refers to new microspheres including pancreatic enzymes, pharmaceutical compositions containing them, and a process to obtain them. The process here described doesn't involve the use of solvents and proves to be remarkably shorter and efficient than the producing methods of the prior arts. The microspheres obtained, including one or more pancreatic enzymes, one or more hydrophilic low-melting polymers and eventual excipients, have an high enzymatic activity, bio-availability and stability. | 2016-05-05 |
20160120816 | LIGNIN MICROCAPSULE AND METHOD OF PRODUCING THE SAME - Disclosed are lignin microcapsules including lignin as a shell material and at least one of oil and a carbonaceous material as a core material. The lignin microcapsules may be formed by carried out polymerization in an oil-in-water emulsion including lignin, oil and water and further including a carbonaceous material. Since lignin has a phenol structure, the microcapsules including lignin may be formed to have antibacterial property. Thus, the lignin microcapsules may be used widely in various fields, such as additives for composite materials. | 2016-05-05 |
20160120817 | A PROCESS FOR PRODUCING MICROCAPSULES COMPRISING AN ACTIVE COMPONENT ENCAPSULATED, PROTECTED AND STABILISED WITHIN A PROTEIN SHELL - A process for producing microencapsulates comprising an active component such as creatine encapsulated within a polymerised hydrolysed whey protein matrix is described. The method comprises the steps of providing a suspension of hydrolysed whey protein and an active component in a carboxylic ester, treating the suspension to generate droplets of the suspension, and immediately curing the droplets by immersion in a basic curing solution, wherein the ester in the suspension reacts with the basic curing solution to release a salt that polymerises the hydrolysed whey protein encapsulating the active component in the presence of black pepper extract, glycerol, phosphate and optionally, astaxanthin and alpha lipoic acid. | 2016-05-05 |
20160120818 | PHARMACEUTICAL COMPOSITIONS COMPRISING VESICLES - The invention relates to pharmaceutical compositions comprising animal vesicles and bacterial vesicles, and to methods for preparing and using them. Animal vesicles and bacterial vesicles fuse to form immunogenic pharmaceutical compositions. The animal vesicular component provides a specific adaptive immune response and the bacterial vesicular component provides adjuventicity. | 2016-05-05 |
20160120819 | METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER - There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described. | 2016-05-05 |
20160120820 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR AND METHOD OF PREPARING THE SAME - A pharmaceutical composition, including: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt thereof. The active ingredient accounts for between 10 and 40 wt. % of the total weight of the pharmaceutical composition. The coating layer includes a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the pharmaceutical composition. The pharmaceutical composition has a diameter of between 0.10 and 0.50 mm. | 2016-05-05 |
20160120821 | DRUG ELUTING SILICONE GEL SHEETING FOR WOUND HEALING AND SCAR REDUCTION - Provided are methods of making devices that can be applied to the skin to promote healing of wounds and the reduction or prevention of scarring. The devices include compositions of various silicone compounds loaded with active pharmaceutical agents. | 2016-05-05 |
20160120822 | COMPOSITION CONTAINING ROTIGOTINE AND USE THEREOF AND TRANSDERMAL PATCH CONTAINING THE COMPOSITION - A Rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in the matrix mixture system. The acrylic pressure-sensitive adhesive may be present in an amount of about 1-25% by weight in the matrix mixture system. The silicone pressure-sensitive adhesive may be present in an amount of about 65-98% by weight in the matrix mixture system. The composition further includes 1-40% of Rotigotine on the basis of the total weight of the composition. The composition provides improved properties in the solubility, release and initial penetration level of Rotigotine. Also disclosed is a transdermal patch that includes the Rotigotine-containing composition, as well as methods of manufacturing and using the Rotigotine-containing composition. | 2016-05-05 |
20160120823 | TRANSDERMAL DELIVERY SYSTEM COMPRISING BUPRENORPHINE - The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising
| 2016-05-05 |
20160120824 | COMPOSITION FOR TOPICAL APPLICATION COMPRISING GLYCEROL AND TANNINS - A preparation for topical application comprising glycerol and plant tannins, wherein the plant tannins have the capacity to bind to glycerol so that the glycerol has filmogen quality. | 2016-05-05 |
20160120825 | STABLE CRYSTAL X-FORM AGOMELATINE TABLET AND PREPARATION METHOD THEREOF - Disclosed are a stable crystal X-form agomelatine tablet and a preparation method thereof. The method comprises the following steps: selecting one or more protective agents, adding the protective agents into pure water, stirring, heating the mixture to 35-40° C., dissolving them until the solution is clear, cooling the solution to room temperature, adding crystal X-form agomelatine, stirring the mixture until homogeneous, and obtaining the protective agents containing the crystal X-form agomelatine for use; and then, after mixing a part of the pharmaceutical excipient until homogeneous, again adding the protective agents containing the crystal X-form agomelatine, mixing and pelletizing them according to a wet method and drying to obtain particles containing the crystal X-form agomelatine; and finally, adding the other pharmaceutical excipients into the particles according to a proportion, mixing them until homogeneous and tabletting them. | 2016-05-05 |
20160120826 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS - A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose. | 2016-05-05 |
20160120827 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS - A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose. | 2016-05-05 |
20160120828 | COLONOSCOPY PREPARATION KIT - Provides is a kit comprising: a) a container; and b) following components placed inside of the container: i) magnesium citrate oral Solution; ii) a laxative in form of an oral pharmaceutical dosage form; iii) a topical formulation for application to the skin to relieve irritation; iii) a container of polyethylene glycol powder; iv) an oral pharmaceutical dosage form for treating nausea; and v) an electrolyte drink mix; wherein the kit is used by a patient to clean the patient's colon prior to a colonoscopy. | 2016-05-05 |
20160120829 | HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTIONS COMPRISING ONE OR MORE CREATINE COMPOUNDS - The present invention provides a hemodialysis solution or concentrate thereof including creatine compound(s), the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof, a method for preparing creatine-containing dialysis solutions and concentrates, and a method for treating patients with dialysis dependent renal failure with creatine compounds to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells of the patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities. Furthermore, in peritoneal dialysis solutions creatine can be used as an osmotic agent preventing side effects caused by high glucose supplementation. | 2016-05-05 |
20160120830 | Autoimmune-Induced Glutamatergic Receptor Dysfunction Methods and Treatments - This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. | 2016-05-05 |
20160120831 | INCREASE OF PROTEIN SYNTHESIS AMELIORATES SYNAPTOPATHY-RELATED NEUROLOGICAL DISORDERS - Disclosed herein is a method for increasing the dendritic spine formation or dendritic spine density in a subject, whom is affected by a dendritic spine defect caused by the impairment in neurofibromin (NF1 protein), valosin-containing protein (VCP), atlastin-1 (ATL1), or superoxide dismutase 1 (SOD1). Accordingly, also disclosed herein is a method for treating a subject having or suspected of having a synaptopathy caused by the impairment in NF1, VCP, ATL1, or SOD1. | 2016-05-05 |
20160120832 | LIPID SCAVENGING IN RAS CANCERS - Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided. | 2016-05-05 |
20160120833 | COMPOSITION AND METHOD FOR TREATING AND RELIEVING MYOPIA - The present invention provides a pharmaceutical composition for treating and/or relieving myopia, the pharmaceutical composition comprises a therapeutically effective amount of an anti-inflammatory agent and a pharmaceutically acceptable carrier; the pharmaceutical composition of the present invention is safe, and can treat and/or relieve myopia by the anti-inflammatory agent. The pharmaceutically acceptable carrier can effectively encapsulate the anti-inflammatory agent at a specific ratio, and the stability and solubility of the pharmaceutical composition can be enhanced. | 2016-05-05 |
20160120834 | CADOTRIL PARTICLES - Cadotril particles suitable for solid or liquid dosage forms are disclosed | 2016-05-05 |
20160120835 | A TOPICAL COMPOSITION - The invention provides a topical composition for cutaneous application which is an oil-in-water emulsion comprising (a) an oily phase, (b) an ingenol derivative in dissolved form; (c) an aqueous phase buffered to a p H of below 4.5, (d) at least one surfactant. | 2016-05-05 |
20160120836 | PHORBOL ESTER COMPOSITIONS AND METHODS OF USE FOR TREATING OR REDUCING THE DURATION OF CYTOPENIA - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia. | 2016-05-05 |
20160120837 | Methods of reducing apolipoprotein C-III - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2016-05-05 |
20160120838 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria. | 2016-05-05 |
20160120839 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria. | 2016-05-05 |
20160120840 | METHOD AND COMPOSITION FOR TREATING NONEROSIVE REFLUX DISEASE - Method and composition for treating a nonerosive reflux disease in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative are provided. | 2016-05-05 |
20160120841 | SUBSTITUTED CHROMANES AND METHOD OF USE - The invention provides for compounds of formula (I) | 2016-05-05 |
20160120842 | AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE - The hemitartrate salt of a compound represented by the following structural formula: | 2016-05-05 |
20160120843 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS - The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders. | 2016-05-05 |
20160120844 | COMPOSITIONS AND METHODS FOR INHIBITING LEISHMANIA - Compositions and methods for inhibiting Leishmaniasis using AIs are provided. Aspects provide compositions and methods for administering AIs alone or in combination with other compounds to infected hosts. | 2016-05-05 |
20160120845 | Methods of Treating Psoriasis Using Allantoin - Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous | 2016-05-05 |
20160120846 | Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents. | 2016-05-05 |
20160120847 | Low Dose Pharmaceutical Composition - This invention provides a low dose pharmaceutical composition comprising deferasirox or a pharmaceutically acceptable derivative thereof and one or more pharmaceutically acceptable excipients. A unit dose of the pharmaceutical composition comprises from about 50 mg to about 100 mg of deferasirox, from about 150 mg to about 200 mg of deferasirox or from about 260 mg to about 350 mg of deferasirox. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox, may be used to treat chronic iron overload or to treat lead toxicity. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox and deferiprone, may be used to treat lead toxicity. This invention also provides a process for preparing the low dose pharmaceutical composition, the process comprising: dissolving or adsorbing or blending deferasirox and at least one excipient to produce a dispersion of deferasirox; and processing the dispersion to produce a desired dosage form. | 2016-05-05 |
20160120848 | SPECIFIC CANCER TREATMENT REGIMES WITH GANETESPIB - Methods of treating certain types of cancer with ganetespib are disclosed. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, and a platinum-containing anticancer agent. Also provided are methods of treating certain types of cancer with p53 mutation by a combination of ganetespib with a taxane derivative, and a platinum-containing anticancer agent. Also provided are methods of treating certain types of cancer with ganetespib in combination with a platinum-containing anticancer agent, and an antimetabolite. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, an anthracycline derivative, and an alkylating antineoplastic agent. Also provided is a pharmaceutical composition comprising ganetespib and one or more other anticancer agents as described above. | 2016-05-05 |
20160120849 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR - A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae | 2016-05-05 |
20160120850 | THIAZOLES AS MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2016-05-05 |
20160120851 | BENZOTHIAZOLE DERIVATIVES AND A USE THEREOF FOR THE TREATMENT OF CANCER - Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof: | 2016-05-05 |
20160120852 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS - Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria. | 2016-05-05 |
20160120853 | TACROLIMUS AND ANALOGUES THEREOF FOR MEDICAL USE - The present invention relates to a method of treating adverse fat accumulation and related conditions with very low doses of tacrolimus or a close structural analogue thereof. In particular this invention relates to treating adverse fat accumulation and/or sarcopenia and/or metabolic syndrome inpatients by administering tacrolimus in very low dose. Most particularly this invention relates to the use of tacrolimus in treating age related fat accumulation. | 2016-05-05 |
20160120854 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions of substituted triazolopyridine compounds of general formula (I) as described and defined herein, to methods of preparing said compositions, and to the use of the compositions for the treatment or prophylaxis of a disease. | 2016-05-05 |
20160120856 | METHOD FOR INHIBITING PLATELET AGGREGATION - A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 μg/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μg/kg/min, wherein the active drug is tirofiban or a salt thereof. | 2016-05-05 |
20160120857 | Anti-Fibrogenic Compounds, Methods and Uses Thereof - Presented herein are methods for treatment of diseases or conditions related to fibrosis. Compounds, or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof provide for the treatment of diseases or conditions related to fibrosis. The methods utilize the compounds kynurenine, kynurenic acid and xanthurenic acid, and various analogues, related structures and pharmaceutical compositions thereof, wherein the compounds are represented by one or more compounds represented by Formulas I, II, or II as set out below: | 2016-05-05 |
20160120858 | PHARMACEUTICAL COMPOSITION CONTAINING CLIOQUINOL FOR TREATING AUTISM SPECTRUM DISORDERS - The present invention relates to a pharmaceutical composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a food composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof. | 2016-05-05 |
20160120859 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR - The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof. | 2016-05-05 |
20160120860 | METHODS AND AGENTS FOR TREATING TYROSINASE-POSITIVE ALBINISM - Methods for treating a subject with tyrosinase-positive albinism; agents and compositions thereof for use in treating tyrosinase-positive albinism; and medicaments for treating tyrosinase-positive albinism are described herein. Such methods; agents and compositions thereof; and medicaments relate to chloroquine or rapamycin or compositions thereof and may further relate to nitisinone used in conjunction with the chloroquine or rapamycin or a composition of either of which. | 2016-05-05 |
20160120862 | Novel Suicidal LSD1 Inhibitors Targeting SOX2-Expressing Cancer Cells - Disclosed are inhibitors of lysine-specific demethylase I (LSD1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating cancers characterized by the presence of Sox2 using the compounds and compositions Also disclosed are methods of treating cancers characterized by the presence of Sox2 using inhibitors of LSD1 and/or histone deacetylation I (HDAC1). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2016-05-05 |
20160120863 | SLC2A TRANSPORTER INHIBITORS - Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula: | 2016-05-05 |
20160120864 | Novel Pyrrole Derivatives - There is provided inter alia novel N-phenyl substituted pyrrole derivatives and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections. | 2016-05-05 |
20160120865 | TOPICAL TREATMENT OF LOCALIZED SCLERODERMA - Disclosed are compositions and formulations for topical administration that contain a tyrosin kinase inhibitor, such as imatinib or nilotinib. The topical compositions or formulations are useful in treating scleroderma. | 2016-05-05 |
20160120866 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. | 2016-05-05 |
20160120867 | STABILIZED PEMETREXED FORMULATION - The present invention relates to a stabilized pemetrexed formulation, and more specifically, to a stabilized pemetrexed formulation comprising acetylcysteine as an antioxidant and sodium citrate as a buffering agent. Additionally, the present invention relates to a pemetrexed formulation filled in a sealed container, comprising pemetrexed or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the oxygen gas content within the headspace of the container is 3 v/v % or less. | 2016-05-05 |
20160120868 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS - The present invention is directed to novel pyrazolopyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities against BTK and/or EGFR T790M and are useful for the treatment of protein kinases mediated diseases and conditions. | 2016-05-05 |
20160120869 | SOLID PHARMACEUTICAL DOSAGE FORM - The present invention relates to a solid pharmaceutical dosage from comprising ticagrelor and ASA as pharmaceutically active agents, to a package for storing the solid pharmaceutical dosage form and to a solid pharmaceutical dosage form for the use in the treatment of certain diseases. | 2016-05-05 |
20160120870 | THE PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN - The present invention relates to a process for the preparation of a pharmaceutical composition comprising rivaroxaban, wherein the process comprises a step of milling a mixture comprising rivaroxaban and at least one hydrophilic binder. | 2016-05-05 |
20160120871 | PHARMACEUTICAL COMBINATIONS OF A PI3K INHIBITOR AND A MICROTUBULE DESTABILIZING AGENT - The present invention relates to a combination comprising (a) a phosphatidylinositol 3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salts thereof, and (b) a microtubule destabilizing agent for simultaneous, separate or sequential use for the treatment of a tumor disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a tumor disease comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the treatment of a tumor disease; and a commercial package thereto. | 2016-05-05 |
20160120872 | RAC1 Inhibitors for Inducing Bronchodilation - The invention relates to a Rac1 inhibitor for use as bronchodilator in a patient in need thereof. The invention provides a Rac1 inhibitor for use in a method for inducing bronchodilation in a patient in need thereof. The invention also relates to a Rac1 inhibitor for use in a method for reducing AHR in a patient in need thereof. | 2016-05-05 |
20160120873 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators - The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative and a positive allosteric AMPA receptor modulator in an amount sufficient to reduce or inhibit respiratory depression caused by the analgesic, anaesthetic, or sedative. | 2016-05-05 |
20160120874 | AGENTS FOR TREATING MULTIPLE MYELOMA - The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, said compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. For this reason, the invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases. | 2016-05-05 |
20160120875 | SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE)BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIBITORS - Methods of treatment of disorders of uncontrolled cellular proliferation, including cancer, by administering substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds to mammals in need thereof. | 2016-05-05 |
20160120876 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER USING PHENOTHIAZINE - The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine. | 2016-05-05 |
20160120877 | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED DELIVERY OF BENZODIAZEPINE ANTAGONISTS - The present invention relates to sustained release formulations of benzodiazepine antagonists and their use. | 2016-05-05 |
20160120878 | DERIVATIVES OF BETULIN - The present invention relates to compounds characterized by having a structure according to the following formula I: | 2016-05-05 |
20160120879 | USE OF SUSTAINED RELEASE DEXAMETHASONE IN POST-CATARACT SURGERY INFLAMMATION - The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery | 2016-05-05 |
20160120880 | BILE ACID-BASIC AMINO ACID CONJUGATES AND USES THEREOF - Compositions and methods for treating diseases or disorders associated with the metabolic syndrome using conjugates of bile acids with basic amino acids or a decarboxylated amino acid such as agmatine are provided. Further provided are bile acid-basic amino acid conjugates including chenodeoxycholic acid with an amino acid selected from arginine, lysine, histidine, ornithine or a decarboxylated amino acid such as agmatine. | 2016-05-05 |
20160120881 | USE OF BUFODIENOLIDES IN DIAGNOSING AND TREATING ESSENTIAL HYPERTENSION - Certain embodiments are directed to methods of identifying patients with essential hypertension by detecting elevated levels of marinobufagenin (MBG) and treating the same with anti-MBG agents. | 2016-05-05 |
20160120882 | COMPOSITION HAVING A BENEFICIAL EFFECT ON THE CARDIOVASCULAR SYSTEM - The present invention is in the field of medical treatment and relates to a formulation for oral administration, such as for instance in the form of tablets or of a powder, which is able to exert a beneficial effect on the cardiovascular system. More in particular, the invention provides a composition for oral administration having a beneficial effect on the cardiovascular system, comprising as active ingredients a mixture of monacolin K, lycopene and vitamin D3. | 2016-05-05 |
20160120883 | ANTI-INFECTIVE HYDROXY-PHENYL-BENZOATES AND METHODS OF USE - The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus | 2016-05-05 |
20160120884 | PHARMACEUTICAL COMPOSITION FOR TREATING DISEASE ASSOCIATED WITH DEMYELINATION OF NEURONS AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION - A method of accelerating remyelination or suppressing demyelination of neurons in a mammal, and a method of treating a disease associated with demyelination of neurons in a mammal. | 2016-05-05 |
20160120885 | FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA - Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (COX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor. | 2016-05-05 |
20160120886 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS - The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment oil for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, bladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof | 2016-05-05 |
20160120887 | TUMOR ERADICATION BY INOSITOL-TRIPYROPHOSPHATE - The present invention relates to various salts of inositol tripyrophosphate including the calcium, lithium, beryllium, magnesium, potassium, strontium, barium, rubidium and cesium salts of inositol tripyrophosphate, compositions comprising these salts, methods of making the various salts, and methods of use of the above salts. Methods of use include administering the above salts in an effective amount in individuals for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis. | 2016-05-05 |
20160120888 | ANTICANCER DRUG - An anti-cancer agent and a cancer cell death inducing agent, containing an inositol phospholipid compound, particularly 1,2-O-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycerol-3-phosphatidyl-inositol, as an active ingredient. | 2016-05-05 |
20160120889 | LIFESPAN EXTENDING AGENT - A lifespan extending agent that is safe for animals, and can easily be ingested in a form that resembles foods. A lifespan extending method is also disclosed. In the lifespan extending agent, a rare sugar usable as a sweetener is contained as an active ingredient. | 2016-05-05 |
20160120890 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS - The invention provides methods, compositions, uses of compositions, assays and kits for modulating brown adipose tissue (BAT) in animals and patients with obesity, insulin resistance and perturbed glucose homeostasis are disclosed. Accordingly, methods, compositions, uses of compositions, and kits are useful for the amelioration of pathological conditions characterized by storage of excess energy, insulin resistance and related metabolic syndromes often associated with obesity. | 2016-05-05 |
20160120891 | COMPOSITIONS FOR USE IN CARTILAGE BREAKDOWN - The present invention relates to use of a composition comprising oleuropein and/or hydroxytyrosol for maintenance joint health or prevention or treatment of joint disorders. In particular, the invention relates to oleuropein for use to prevent or treat cartilage breakdown. | 2016-05-05 |
20160120892 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. | 2016-05-05 |
20160120893 | METHODS AND COMPOSITIONS RELATING TO MODULATION OF THE PERMEABILITY OF THE BLOOD BRAIN BARRIER - Described herein are methods and compositions relating to modulating the permeability of the blood-brain barrier, e.g. increasing or decreasing the permeability of the blood-brain barrier for therapeutic purposes. | 2016-05-05 |
20160120894 | USE OF ADENOSINE ASPARTATE IN THE DIFFERENTIAL ACTIVATION OF MACROPHAGES IN INFLAMMATORY-FIBROGENIC PROCESSES AND ITS REVERSAL - The present invention relates to the use of adenosine aspartate for differential activation of macrophages in inflammatory-fibrogenic processes and its reversal. | 2016-05-05 |
20160120895 | MicroRNAs useful for Treating Ovarian Cancer - Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients. | 2016-05-05 |
20160120896 | POLYSACCHARIDE COMPOSITIONS AND RELATED METHODS - The disclosure provides LMWH preparations and methods of analyzing LMWH preparations having at least one chain having a glycol split uronic acid residue (UG) in the preparation for structural signatures, and methods of producing such preparations based upon the analysis. | 2016-05-05 |
20160120897 | DEXTRAN SULFATE FOR USE IN MOBILIZATION OF CELLS - Dextran sulfate in a range of 3500 and 9500 Da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration. | 2016-05-05 |
20160120898 | METHODS AND COMPOSITIONS FOR THE DISRUPTION OF BIOFILMS AND TREATMENT OF DISORDERS CHARACTERIZED BY THE PRESENCE OF BIOFILMS - Methods and compositions are provided for the disruption of biofilms and the treatment of disorders characterized by the presence of biofilms and/or abnormally viscous and/or cohesive bodily secretions, such as mucus and sputum. Disorders that can be effectively treated using the disclosed compositions and methods include cystic fibrosis (CF), endocarditis, urinary tract infections, middle-ear infections, chronic sinusitis, gingivitis, periodontal disease, bronchiectasis, chronic obstructive pulmonary disease (COPD), asthma, bronchitis, neonatal meconium aspiration syndrome, smokers' cough, chronic tonsillitis, chronic vaginitis, and fungal or bacterial infections. The compositions, which contain an effective amount of trisodium citrate and ammonium chloride, may be administered alone or in combination with one or more known therapeutic agents. | 2016-05-05 |